QCM Cayman’s Amicus Therapeutics FOLD Stock Holding History

QCM Cayman’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-14,437	Closed	-$138K	–	67
2018 Q4	$138K	Buy	+14,437	New	+$159K	0.56%	80

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

QCM Cayman's FOLD Position: Q1 2019 in Review

QCM Cayman sold out of Amicus Therapeutics (FOLD) in Q1 2019, closing a stake of 14,437 shares — an estimated $138K sold.

QCM Cayman first reported a position in FOLD in Q4 2018 and held it in 1 quarter. The position peaked at $138K in Q4 2018. 205 funds tracked by Wall St. Rank hold FOLD as of Q1 2019.

QCM Cayman reported no remaining Amicus Therapeutics position as of Q1 2019 after selling out during the quarter.
QCM Cayman sold 14,437 Amicus Therapeutics shares in Q1 2019, an estimated $138K.
QCM Cayman first reported a position in Amicus Therapeutics in Q4 2018 and held it in 1 quarter.
QCM Cayman's Amicus Therapeutics position peaked at $138K in Q4 2018.
205 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2019.

Based on QCM Cayman's 13F filing for Q1 2019, filed 13 May 2019.